anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to drugs and foods produced by applying a method whereby a biological activity can be efficiently exerted in the case of orally administering a biologically active protein. <??>The oral composition according to the present invention contains at least one biologically active protein as the active ingredient and has a means of controlling the release. According to the composition of the present invention, at least 10% of the active ingredient is delivered to the lower digestive tract while sustaining its activity. Namely, the biologically active protein is not degraded in the stomach but delivered to the small intestine, which makes it possible to ensure the exertion of its drug's effect exert a hitherto unknown effect. It is preferable that the biologically benefical active protein contained in the composition according to the present invention is lactoferrin, immunoglobulin, lysozyme, an amylase, a protease, a lipase or a digestive enzyme inhibitor.
Epigenetic dysregulation drives aberrant transcriptional programs playing a critical role in hepatocellular carcinoma (HCC), which may provide novel insights into the heterogeneity of HCC. This study performed an integrated exploration on the epigenetic dysregulation of miRNA and methylation. We discovered and validated three patterns endowed with gene-related transcriptional traits and clinical outcomes. Specially, a stemness/epithelial-mesenchymal transition (EMT) subtype was featured by immune exhaustion and the worst prognosis. Besides, MMP12, a characteristic gene, was highly expressed in the stemness/EMT subtype, which was verified as a pivotal regulator linked to the unfavorable prognosis and further proven to promote tumor proliferation, invasion, and metastasis in vitro experiments. Proteomic analysis by mass spectrometry sequencing also indicated that the overexpression of MMP12 was significantly associated with cell proliferation and adhesion. Taken together, this study unveils innovative insights into epigenetic dysregulation and identifies a stemness/EMT subtype-specific gene, MMP12, correlated with the progression and prognosis of HCC.
In the second group there will be patients in who will be given the TAP block. The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacaine in 40 ml bilaterally. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
Subjects need to take the Chinese herbal medicine (Shenlingcao oral liquid) 200 ml twice per day for 4 weeks. Shenlingcao oral solution is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
Reducing plaque lipid content and enhancing plaque stability without causing extensive apoptosis of foam cells are ideal requirements for developing a safe and effective treatment of atherosclerosis. In this study, we synthesized IR780-Gd-OPN nanomicelles by conjugating osteopontin (OPN) and loading a gadolinium-macrocyclic ligand (Gd-DOTA) onto near-infrared dye IR780-polyethylene glycol polymer. The nanomicelles were employed for mild phototherapy of atherosclerotic plaques and dual-mode imaging with near-infrared fluorescence and magnetic resonance. In vitro results reveal that the mild phototherapy mediated by IR780-Gd-OPN nanomicelles not only activates heat shock protein (HSP) 27 to protect foam cells against apoptosis but also inhibits the nuclear factor kappa-B (NF-κB) pathway to regulate lipid metabolism and macrophage polarization, thereby diminishing the inflammatory response. In vivo results further validate that mild phototherapy effectively reduces plaque lipid content and size while simultaneously enhancing plaque stability by regulating the ratio of M1 and M2-type macrophages. In summary, this study presents a promising approach for developing a safe and highly efficient method for the precise therapeutic visualization of atherosclerosis. STATEMENT OF SIGNIFICANCE: The rupture of unstable atherosclerotic plaques is a major cause of high mortality rates in cardiovascular diseases. Therefore, the ideal outcome of atherosclerosis treatment is to reduce plaque size while enhancing plaque stability. To address this challenge, we designed IR780-Gd-OPN nanomicelles for mild phototherapy of atherosclerosis. This treatment can effectively reduce plaque size while significantly improving plaque stability by increasing collagen fiber content and elevating the ratio of M2/M1 macrophages, which is mainly attributed to the inhibition of the NF-κB signaling pathway by mild phototherapy-activated HSP27. In summary, our proposed mild phototherapy strategy provides a promising approach for safe and effective treatment of atherosclerosis.
Chronic inflammation is an important pathogenetic factor that leads to the progression of Alzheimer's disease (AD), and specialized pro-resolving lipid mediators (SPMs) play critical role in regulating inflammatory responses during AD pathogenesis. Maresin1 (MaR1) is the latest discovered SPMs, and it is found that MaR1 improves AD cognitive impairment by regulating neurotrophic pathways to protect AD synapses and reduce Aβ production, which made MaR1 as candidate agent for AD treatment. Unfortunately, the underlying mechanisms are still largely known. In this study, the AD mice and cellular models were subjected to MaR1 treatment, and we found that MaR1 reduced Aβ production to ameliorate AD-related symptoms and increased the expression levels of ADAM10/17, sAPPα and sAPPβ to exert its anti-inflammatory role. In addition, as it was determined by Western Blot analysis, we observed that MaR1 could affected the neuroprotective signal pathways. Specifically, MaR1 downregulated p57NTR and upregulated TrkA to activate the p75NTR/TrkA signal pathway, and it could increase the expression levels of p-PI3K and p-Akt, and downregulated p-mTOR to activate the PI3K/AKT/ERK/mTOR pathway. Finally, we verified the role of ADAM10/17 in regulating AD progression, and we found that silencing of ADAM10/17 inactivated the above neuroprotective signal pathways to aggravate AD pathogenesis. In conclusion, MaR1 is verified as potential therapeutic agent for AD by eliminating Aβ production, upregulating ADAM10/17, sAPPα and sAPPβ, and activating the neuroprotective p75NTR/TrkA pathway and the PI3K/AKT/ERK/mTOR pathway.
Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals, primarily those without light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is \> 24 hours and earlier and earlier if \< 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping.

This will be a multicenter, randomized, double-masked, placebo-controlled, parallel study. The study has two phases: the pre-randomization phase followed by either the randomization phase or the open-label extension (OLE). The pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated, a circadian period (τ) estimation segment, and a variable-length in-phase transition segment in which subjects will wait to start treatment until their circadian phase is aligned with their target bedtime. Subjects that meet all entry criteria for the study will enter the randomization phase. During the randomization phase, subjects will be asked to take either 20 mg tasimelteon or placebo approximately 1 hour prior to their target bedtime for 26 weeks in a double-masked fashion. Subjects who have a τ greater than 24.0 and meet all entry criteria but that are ineligible for the randomization phase due to their τ estimate may be given the opportunity to participate in the OLE phase. During the OLE phase, subjects will take open-label 20mg tasimelteon for 26 weeks.
Personal Information Form (PIF) and Beck Anxiety Scale (BAS) were administered to this group by face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After 1 week, BAS, blood tests and ECG have applied again.
Amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it.

It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. When it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. Amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved.

Amitriptyline hydrochloride should not be given with cisapride due to the potential for increased QT interval and increased risk for arrhythmia. This drug is not recommended for use during the acute recovery phase following myocardial infarction.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic which contains an oily ingredient in a large amount, has a performance as an oily cleansing, and is suitable for cleansing little giving irritation, when used, in dependence on the characteristics of foams.  <P>SOLUTION: This foam-like aerosol cosmetic comprising (1) a Cydonia oblonga seed extract, (2) a nonionic surfactant, and (3) an oil is characterized in that the content of the oil is 50 to 95 wt.%. An extraction solvent for the Cydonia oblonga seed extract is preferably alcohols, more preferably a polyhydric alcohol. The polyhydric alcohol is particularly preferably 1,3-butanediol. The combination of the nonionic surfactant is preferably a form containing a hydroxyl group-having acylated polyglycerol.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PROBLEM TO BE SOLVED: To provide a composition for treating and preventing a disease, a composition for treating and preventing hypertension, a composition for treating and preventing hyperlipemia, and a composition for treating and preventing obesity, having a low possibility of causing a side effect and having an excellent activity. SOLUTION: The composition for treating and preventing a disease containing a dried matter or an extract of the strain of Lyopyllum decastes. It is preferable that the composition mainly contains a hot water extract of the dried powder of the strain of Lyopyllum decastes. It is preferable that the composition is prepared by condensing the hot water extract, adding a vehicle and pulverizing them. In the composition, the disease is hypertension, and the composition is to be used for treating and preventing hypertension. The disease treated and prevented by the composition is obesity, hyperlipemia or hyperlipemia.
Relaxin preparations containing impurities having an isoelectric point higher than that of relaxin are purified by bringing an aqueous solution having a pH greater than the isoelectric point of relaxin, say 7-8.6, into contact with a carboxylic acid type cation exchange resin buffered to the same pH, and washing unabsorbed material from the resin with a buffered solution of pH not greater than that of the buffered resin thereby recovering the purified relaxin.  The resin may be regenerated by eluting the absorbed impurities with acid. Relaxin preparations containing impurities of lower isoelectric point are purified by bringing an aqueous solution of lower pH than the isoelectric point of relaxin, say 4.5-7, into contact with the said resin buffered to the same pH, and washing unabsorbed material from the resin, purified relaxin being then obtained by washing the resin with acid.  Suitable resins are those formed by condensation of a phenolic carboxylic acid and an aldehyde, or preferably, copolymers of acrylic or methacrylic acid and divinyl benzene wherein the latter constitutes 2 1/2 -5 per cent of the resin composition.  Prior to or after purification, electrolytes are removed by dialysis, or by treatment with a sulphonic acid type cation exchange resin (acid form), followed by treatment with an anion exchange resin.  The product may be freeze-dried.
Discloses a liquid pharmaceutical composition comprising follicle-stimulating hormone (FSH) or a variant thereof, and both benzalkonium chloride and benzyl alcohol as preservatives. The composition may further comprise an antioxidant (e.g. methionine), surfactants (e.g. polysorbate) or tonicity modifier (e.g. sugar or alcohol). Further discloses the use of the composition for the manufacture of a medicament for treatment of conditions associated with deficient FSH production.
The enhanced MDA Strategy 1 consists of a routine community-wide MDA followed by two additional rounds targeted to children age 6 months to 9 years. The additional rounds of treatment will occur 2 weeks apart and will begin 1 week after the community-wide MDA.
Cytostatic-oncolytic compound, obtaining procedure and external and internal use thereof. Cytostatic-oncolytic compound based on plant extracts and procedure for obtaining them. The product comprises an alcoholic emulsion of dried plants, with the following composition per 100 ml of ethyl alcohol; 2-5 g of vitis vinifera, 2-5-6 g of rosemary, 2-5-6 g of walnut leaves, 2-5-6 g of nettle and 2-5-6 g of nettle and 2- 5-6 g of hypericum. The process comprises subjecting a mixture formed by the ethyl alcohol and the mentioned amounts of said dried plants in a closed vessel for 7 to 14 days followed by filtration of the resulting extract to room temperature maceration and with sporadic stirring. Application for the treatment and prevention of internal and articular psoriasis, squamous cell carcinoma, actinic keratosis (solar keratosis), seborrheic dermatitis of the scalp, dandruff, contact dermatitis, dermatitis herpetiformis. (Machine-translation by Google Translate, not legally binding)
See FDA-approved patient labeling (Patient Information).

Patients should be informed that anticholinergic agents, such as darifenacin, may produce clinically significant adverse effects related to anticholinergic pharmacological activity including constipation, urinary retention and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment. Because anticholinergics, such as darifenacin, may produce dizziness or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug’s effects have been determined. Patients should read the patient information leaflet before starting therapy with darifenacin. 

Patients should be informed that darifenacin may produce clinically significant angioedema that may result in airway obstruction. Patients should be advised to promptly discontinue darifenacin therapy and seek immediate medical attention if they experience edema of the tongue or laryngopharynx, or difficulty breathing. 

Darifenacin extended-release tablets should be taken once daily with water. They may be taken with or without food, and should be swallowed whole and not chewed, divided or crushed.
Neutropenic fever in adults undergoing chemotherapy for cancer treatment is a medical emergency and has been the focus of numerous studies. However, there is a paucity of data about non-chemotherapy induced neutropenic fever (non-CINF). We retrospectively reviewed 383 adults with neutropenic fever hospitalized at one academic medical center between October 2015 and September 2020 to characterize the frequency, causes, and outcomes of non-CINF. Twenty-six percent of cases of neutropenic fever were non-chemotherapy induced. Among these, the major causes of neutropenia were hematologic malignancy, infection, and rheumatologic disease, and the major causes of fever were infections. Patients with non-CINF had a higher 30-day mortality than those with chemotherapy induced neutropenic fever (25% vs 13%, P = .01). Non-CINF constituted > 25% of neutropenic fever events in hospitalized adults and was associated with a high mortality rate.
The present invention relates to an injection preparation of the water soluble phosphate of azithromycin and a preparation method thereof, which relates to the new water soluble phosphoric acid salt of macrolide antibiotic azithromycin, an injection thereof for injecting and a preparation method thereof. The preparation method of the water soluble phosphoric acid salt of azithromycin is characterized in that the azithromycin and phosphoric acid with proper quantity are dissolved in a solution, and the mole number of H3PO4 is 1.8 to 2.5 times than that of azithromycin. Azithromycin phosphate obtained by the preparation method is prepared by the combination of azithromycin and a dihydro hydrogen group with two moles. A molecular formula is C38H72N2O12. (H2PO4). The azithromycin phosphate of the present invention has good stability to moisture. Even if the azithromycin phosphate of the present invention is placed for 2 days under the conditions of 75% of relative moisture and at the temperature of 25 DEG C, weight is just increased by approximate 3%. Appearance has no change and a dried content is unchanged. The salt is reserved for 6 month in a high-temperature closed container, and the clarity, the pH value and the appearance of the salt have no change. A content is lowered by 2%. Preparation is convenient, and technical conditions are easy to control.
No formal drug interaction studies have been conducted with TREXIMET.

Monoamine Oxidase Inhibitors: TREXIMET is contraindicated in patients taking MAO-A inhibitors (see CONTRAINDICATIONS and PRECAUTIONS: Drug Interactions). Treatment with MAO-A inhibitors generally leads to an increase of sumatriptan plasma levels. This interaction has not been seen with an MAO-B inhibitor.

Alcohol: The effect of alcohol consumption on the pharmacokinetics of TREXIMET has not been studied. Alcohol consumed 30 minutes prior to sumatriptan ingestion had no effect on the pharmacokinetics of sumatriptan.
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli
A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.
PROBLEM TO BE SOLVED: To provide a makeup product having a combination of characteristics, such as transfer resistance, migration resistance, staying power, comfort, non- dehydrating effect and gloss, simultaneously. SOLUTION: The makeup product for the beauty treatment of the skin, the lip and or the outer skin contains a first and a second compositions. The first composition comprises a first physiologically acceptable medium, polymer particles and at least one first coloring agent both contained within the medium. The polymer particles are dispersed within a liquid phase and its surface is stabilized with a stabilizer. The second composition is comprised of a second physiologically acceptable medium and at least one second coloring agent contained within the medium. The makeup product is characterized by that one of the coloring agents is an angular dependent pigment and the other is a monochromatic pigment.
A preparation method of a dental phosphate embedding material, an embedding material and application thereof, in particular to a preparation method of a phosphate series embedding material and a matched embedding liquid. The embedding material is prepared by respectively grinding 30-50 parts of quartz, 20-40 parts of cristobalite, 10-40 parts of alumina, 10-30 parts of mullite, 4-9 parts of magnesium oxide, 5-12 parts of ammonium dihydrogen phosphate, 4-8 parts of magnesium dihydrogen phosphate, 1-5 parts of magnesium ammonium phosphate hexahydrate and the like to a certain fineness and uniformly mixing. The embedding liquid consists of 80-90 parts of water, 2-6 parts of boric acid, 4-16 parts of silica sol and the like. Mixing the embedding material and the embedding liquid according to the liquid-solid ratio of 0.11-0.25, and uniformly stirring in a vacuum stirrer to obtain the dental casting mold. The phosphate embedding material has good fluidity, can be fully wetted with wax patterns, has a thermal expansion coefficient matched with hot-die-cast glass ceramics, has good exhaust effect, can avoid cracking in the die-casting process, has finer and finer integral granularity, and saves the grinding and polishing time of the restoration after die-casting. The strength not only meets the die-casting requirement, but also can easily remove the embedded material after die-casting.